Evidence map›Paper›PMID 36073208›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2022

[High expression of MYBL2 promotes progression and predicts a poor survival outcome of prostate cancer].

M Yang, X Zhu, Y Shen, Q He, Y Qin, Y Shao, L Yuan, H Ye

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

M YangDepartment of Urology, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210017, China.
X ZhuDepartment of Urology, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210017, China.
Y ShenDepartment of Urology, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210017, China.
Q HeDepartment of Urology, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210017, China.
Y QinDepartment of Urology, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210017, China.
Y ShaoDepartment of Urology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China.
L YuanDepartment of Urology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.
H YeDepartment of Urology, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210017, China.
Nanjing University of Chinese Medicine · CNShanghai University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the correlation of MYB proto-oncogene like 2 (MYBL2) with biological behaviors and clinical prognosis of prostate cancer (PCa).

methodsWe detected Mybl2 mRNA expression in 45 pairs of PCa and adjacent tissues using real-time quantitative PCR, and analyzed the correlation of high (23 cases) and low expression (22 cases) of

results

conclusion

Indexed as

Cell Cycle ProteinsProstatic NeoplasmsTrans-ActivatorsAnimalsCell ProliferationHumansKaplan-Meier EstimateMaleMiceMice, NudePrognosisTumor MicroenvironmentCell Cycle ProteinsMYBL2 protein, humanTrans-Activatorscell invasioncell proliferationMybl2prognosisprostate cancertumor-bearing mice

Identifiers

PMID36073208
PMCPMC9458535
OpenAlexW4294991648

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.